首页> 外文期刊>Transfusion medicine >Network geometry of evidence from randomised controlled trials addressing donor selection and source of haematopoietic progenitor cells used in allogeneic transplantation: a systematic scoping review
【24h】

Network geometry of evidence from randomised controlled trials addressing donor selection and source of haematopoietic progenitor cells used in allogeneic transplantation: a systematic scoping review

机译:来自随机对照试验的网络几何学,用于解决同种异体移植中使用的供体选择和血外祖细胞来源:系统范围审查

获取原文
获取原文并翻译 | 示例
           

摘要

SUMMARY Background and Methods A scoping review of randomised controlled trials (RCTs) addressing source of cells and choice of donor for allogeneic haematopoietic cell transplantation (HCT) was performed to create a network of best evidence that allows us to identify new potential indirect comparisons for the strategic development of future studies that connect to the existing evidence network. Results A total of 19 eligible RCTs (2589 total patients) were identified. Nine studies (1566 patients) compared clinical outcomes following the use of peripheral blood progenitor cells (PBPCs) with bone marrow (BM) from matched related donors (eight studies) or matched unrelated donors (one study). The remaining studies compared BM or PBPCs with various methods of BM stimulation or manipulation (six studies), compared different methods of surface molecule‐based selection and/or depletion of grafts (two studies) or compared the optimal number of units for paediatric cord blood transplantation (two studies). No published RCTs compared different types of donors. The geometry of the evidence network was analysed to identify opportunities for potential novel indirect comparisons and to identify opportunities to expand the network. Few indirect comparisons are currently feasible due to small sample size and heterogeneity in patient diagnoses and demographics between treatment nodes in the network. Conclusion More RCTs that enrol greater numbers of similar patients are needed to leverage the current evidence network concerning donor choice and source of cells used in allogeneic HCT.
机译:摘要背景和方法对随机对照试验(RCT)的范围审查进行了调查(RCTS),用于解决异基因血包膜细胞移植(HCT)的组织源和供体的选择,以创建一个最佳证据网络,使我们能够识别新的潜在间接比较联系现有证据网络的未来研究的战略发展。结果共有19个符合条件的RCT(2589名患者总患者)。九项研究(1566名患者)与骨髓(BM)使用来自匹配的相关供体(八项研究)或匹配的无关捐助者(一项研究)后比较使用外周血祖细胞(PBPC)进行临床结果。剩余的研究比较了BM或PBPC的各种BM刺激或操纵(六项研究),与移植物(两项研究)的基于表面分子的选择和/或耗竭的不同方法进行了不同的方法,或者比较了儿科脐带血的最佳单位数移植(两项研究)。没有公开的RCT比较不同类型的捐助者。分析了证据网络的几何形状,以确定潜在的新型间接比较的机会,并确定扩大网络的机会。目前,由于网络中的治疗节点之间的患者诊断和人口统计学中的小样本大小和异质性,很少有间接比较目前是可行的。结论需要更多RCT,以利用更多数量的类似患者来利用当前有关供体选择的证据网络和同种异体HCT中使用的细胞来源。

著录项

  • 来源
    《Transfusion medicine》 |2018年第5期|共9页
  • 作者单位

    Blood and Marrow Transplantation Program Department of Medicine (Hematology)University of;

    Blood and Marrow Transplantation Program Department of Medicine (Hematology)University of;

    Blood and Marrow Transplantation Program Department of Medicine (Hematology)University of;

    Blood and Marrow Transplantation Program Department of Medicine (Hematology)University of;

    Information ServicesThe Ottawa HospitalOttawa ON Canada;

    Clinical Epidemiology ProgramOttawa Hospital Research InstituteOttawa ON Canada;

    Blood and Marrow Transplantation Program Department of Medicine (Hematology)University of;

    Blood and Marrow Transplantation Program Department of Medicine (Hematology)University of;

    Clinical Epidemiology ProgramOttawa Hospital Research InstituteOttawa ON Canada;

    Blood and Marrow Transplantation Program Department of Medicine (Hematology)University of;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

    bone marrow; cell source; donor; haematopoietic; network geometry; randomised controlled trials; stem and progenitor cells; transplant;

    机译:骨髓;细胞来源;供体;血包血;网络几何;随机对照试验;茎和祖细胞;移植;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号